## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	'AL
OMB Number:	3235-0287
Estimated average burd	den
hours per response	0.5

longer subject to Section 16. Form 4 or Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Re	esponses)														
1. Name and Address of Reporting Person * HOFFMAN ROBERT				2. Issuer Name and Ticker or Trading Symbol DelMar Pharmaceuticals, Inc. [DMPI]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O DELMAR PHARMACEUTICALS, INC., SUITE 720-999 WEST BROADWAY				3. Date of Earliest Transaction (Month/Day/Year) 04/30/2019							Officer (give ti	tle below)	Other (s	pecify below)	
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)					_X_ Fe	6. Individual or Joint/Group FilingCheck Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person					
VANCOUVER, A1 V5Z 1K5 (City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
		Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)  Code (Instr. 8)  Code		(Instr. 8)  Code	(A) or Disposed of (D) (Instr. 3, 4 and 5)  V Amount (A) or (D) Price		(D) Owne Trans	Owned Following Reported Transaction(s) (Instr. 3 and 4)			7. Nature Ownership Form: Direct (D) Ownership Ownership (Instr. 4)			
	Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	1117	3A. Deemed Execution Date, if	4. f Transaction Code		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect (I)	(Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Performance Stock Units	<u>(1)</u>	04/30/2019		D			200,000	<u>(1)</u>	07/07/2022	Common Stock	200,000	\$ 0	0	D	

## **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
HOFFMAN ROBERT C/O DELMAR PHARMACEUTICALS, INC. SUITE 720-999 WEST BROADWAY VANCOUVER, A1 V5Z 1K5	X					

# **Signatures**

/s/ Anthony Scott Praill, attorney-in-fact for Robert E. Hoffman	05/01/2019
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Each performance stock unit represents the right to receive one share of common stock, to vest upon achievement of specified targets related to the Company's financial performance. Such performance stock units were unvested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.